• METTL17 Regulates Ferroptosis via Mitochondrial Translation

  2026-06-29

  This study uncovers METTL17 as a key mitochondrial regulator of ferroptosis resistance in colorectal cancer, acting through the modulation of mitochondrial RNA methylation and translation. By linking METTL17-driven mitochondrial processes to tumorigenesis and ferroptosis defense, the findings highlight METTL17 as a promising target for sensitizing tumors to ferroptosis-based therapies.

• USP7 Controls Macrophage Polarization via PKM2 in Pancreatit

  2026-06-29

  This study uncovers how ubiquitin-specific protease 7 (USP7) regulates macrophage polarization during severe acute pancreatitis (SAP) by modulating PKM2-dependent metabolic reprogramming. The findings establish a mechanistic link between USP7, glycolytic control, and inflammatory macrophage responses, identifying PKM2 as a potential metabolic checkpoint in SAP pathogenesis.

• Silybin A: Silymarin-Derived Precision for Liver Disease Res

  2026-06-28

  Silybin A, the principal active of Silymarin, stands apart as a rigorously characterized, high-purity hepatoprotective agent for liver disease and metabolic research. This article unpacks advanced workflows, troubleshooting strategies, and real-world protocol enhancements using APExBIO's Silybin A, with actionable insights for experimental success.

• Fluorescent mRNA Tools: Advancing Delivery and Translation

  2026-06-27

  This thought-leadership article provides translational researchers with a strategic, mechanistic, and competitive analysis of mRNA delivery technology, focusing on the ARCA Cy3 EGFP mRNA (5-moUTP) from APExBIO. Integrating insights from recent advances in lipid nanoparticle (LNP) design and nucleoside modification, it bridges the latest reference literature with actionable guidance for experimental design, validation, and reproducibility. The piece emphasizes real-time imaging, immune evasion, and workflow optimization, offering a forward-looking perspective on the maturation and future impact of fluorescent mRNA tools in mammalian cell models and translational medicine.

• Driving Translational IBD Research: DSS Models & Epithelial

  2026-06-26

  Explore how Dextran sulfate sodium salt (DSS, MW 35000-45000) advances mouse models of inflammatory bowel disease by mechanistically linking epithelial damage induction to cutting-edge repair circuits involving GPR35-KLF5. This article delivers strategic guidance for translational researchers, protocol optimization tips, and a forward-looking perspective on bridging preclinical and clinical insights.

• Anlotinib Hydrochloride: Mechanistic Insights and Next-Gen A

  2026-06-26

  Explore how Anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, redefines angiogenesis research through unique mechanistic insights, advanced assay strategies, and comparative analysis beyond standard protocols. Unlock actionable guidance for cancer research using cutting-edge scientific evidence.

• CBX2–HDAC1 Complex Suppresses Tumor Immunogenicity via IFN P

  2026-06-25

  The reference study reveals that CBX2 forms a noncanonical corepressor complex with RACK1 and HDAC1 to suppress interferon signaling, thereby reducing tumor immunogenicity and impeding immunotherapy efficacy. This mechanism highlights a new epigenetic target for enhancing cancer immunotherapy outcomes.

• Thiothixene: Rethinking Antipsychotic Research for Translati

  2026-06-25

  Explore how Thiothixene, a classic antipsychotic agent, is reshaping translational research by bridging dopamine signaling antagonism with innovative immune modulation. This article delivers mechanistic insights, protocol guidance, and strategic context for advancing both neuropsychiatric and immunological discovery—moving far beyond standard product summaries.

• Mitoxantrone: Beyond Resistance—Advanced Insights for Transl

  2026-06-24

  Explore Mitoxantrone as a topoisomerase II inhibitor and apoptosis inducer in B-CLL cells, with a deep dive into resistance mechanisms and practical assay optimization. This article offers new scientific perspectives and actionable guidance for translational oncology researchers.

• BCL-XL Inhibitor A-1155463: Selectivity and Evidence in Canc

  2026-06-23

  BCL-XL inhibitor A-1155463 is a potent, selective compound for targeting BCL-XL in cancer research. Its nanomolar affinity and superior selectivity over earlier inhibitors enable precise apoptosis induction in BCL-XL-dependent cells. Supported by robust preclinical evidence, A-1155463 is a critical tool in dissecting drug resistance mechanisms in solid tumors and hematological malignancies.

• Elobixibat Hydrate in Chronic Idiopathic Constipation: Mecha

  2026-06-23

  This article reviews how elobixibat hydrate, as detailed by Acosta and Camilleri, functions as a selective ileal bile acid transporter inhibitor to improve chronic idiopathic constipation (CIC). By elucidating its mechanism, clinical impact, and comparison with standard therapies, the article informs research design and translational strategies in gastrointestinal pharmacology.

• Dabigatran Etexilate: Direct Thrombin Inhibitor in Coagulati

  2026-06-22

  Dabigatran etexilate delivers precise, rapid, and predictable inhibition of thrombin for advanced anticoagulant research, especially in atrial fibrillation and stroke prevention models. Distinct from traditional agents, it streamlines workflows, reduces monitoring burdens, and offers unique troubleshooting flexibility for both in vitro and in vivo studies.

• 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine:

  2026-06-22

  5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine from APExBIO enables robust, reproducible α2-adrenergic receptor agonist studies, especially in immune modulation and osteosarcoma recurrence models. This article details applied workflows, critical protocol parameters, and practical troubleshooting for maximizing translational insights.

• Practical Use of Annexin V-FITC/7-AAD Apoptosis Kit (K1139)

  2026-06-21

  The Annexin V-FITC/7-AAD Apoptosis Kit is designed for rapid, reliable detection of apoptotic and necrotic cells, streamlining cell viability and cytotoxicity assays via flow cytometry or fluorescence microscopy. This product is best suited for workflows focused on phosphatidylserine exposure and membrane integrity—not for deep mechanistic or pathway analyses.

• Acifran and the Next Frontier in Lipid Metabolism Research

  2026-06-20

  This article unpacks the mechanistic and translational impact of Acifran, a selective HM74A/GPR109A and GPR109B agonist, in lipid metabolism research. Integrating structural biology breakthroughs and practical workflow strategies, we chart how Acifran is empowering a new era of precision metabolic disorder research and outline recommendations for translational scientists seeking to advance the field.

436 records 12/30 page Previous Next First page 上5页 1112131415 下5页 Last page